Company: TELO
Filing Date: 2025-05-15
Form Type: 8-K
Source: 0001641172-25-010518
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-15
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
May 15, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced the identification of Telomir-Ag2 as a novel drug candidate following
successful preclinical validation of its antimicrobial activity. Telomir-Ag2 is a stabilized Silver(II) complex developed using the Company’s
proprietary Telomir-1 platform.

In
a recent Minimum Inhibitory Concentration (MIC) study, Telomir-Ag2 demonstrated broad-spectrum antibacterial activity against both Gram-positive
and Gram-negative strains, including methicillin- and aminoglycoside-resistant Staphylococcus aureus

This
development builds on the Company’s previously announced scientific achievement in stabilizing Silver(II) in a biologically compatible
form. Silver(II) is known for its high oxidative potential and potent antimicrobial properties but has historically been considered too
unstable for use in medicine. The ability to stabilize and preserve its activity represents a notable advancement in the field of antimicrobial
science.

The
Company believes these results may have potential implications for addressing drug-resistant infections in high-risk settings, such as
burn wounds and post-surgical complications. Telomir plans to proceed with formulation development and evaluate strategic and regulatory
pathways to advance Telomir-Ag2.

For
additional details, please refer to the press release issued on May 15, 2025, available on the Company’s website at www. telomirpharma. com.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                    TELOMIR                                      
  Dated:            By:                       /s/                
                    Name:                     Erez               
                    Title:                    Chief